# Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)

> **NCT05981131** · — · ACTIVE_NOT_RECRUITING · sponsor: **ImmunityBio, Inc.** · enrollment: 6 (actual)

## Conditions studied

- Non Muscle Invasive Bladder Cancer

## Interventions

- **DRUG:** N803 plus Bacillus Calmette-Guerin (BCG)

## Key facts

- **NCT ID:** NCT05981131
- **Lead sponsor:** ImmunityBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-08-17
- **Primary completion:** 2033-08-30
- **Final completion:** 2033-08-30
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05981131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05981131, "Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT05981131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*